Virtual Library

Start Your Search

Oliver Rua



Author of

  • +

    EP1.16 - Treatment in the Real World - Support, Survivorship, Systems Research (ID 206)

    • Event: WCLC 2019
    • Type: E-Poster Viewing in the Exhibit Hall
    • Track: Treatment in the Real World - Support, Survivorship, Systems Research
    • Presentations: 1
    • Now Available
    • Moderators:
    • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
    • +

      EP1.16-11 - Immunotherapy in NSCLC: Real World Experience in a Peruvian Population (Now Available) (ID 1035)

      08:00 - 18:00  |  Author(s): Oliver Rua

      • Abstract
      • Slides

      Background

      Checkpoint inhibitors drugs, have achieved positive results above chemotherapy in 2nd line and 1st line for specific populations with lung cancer. Nowadays, investigations continue studying biomarkers which could be useful as predictive factors of response as if inflammatory markers might have some role.

      Method

      The study design included patients with non-small cell lung cancer (NSCLC) that receivedimmunotherapy with “Pembrolizumab” or “Nivolumab” in two private cancer centers of reference since January 2015 until January 2018. The adverse effects were evaluated by medical oncologists and classified by CTCAE v 4.0. The response were assessed by RECIST criteria. Furthermore, inflammatory markers results were obtained from blood work performed before immunotherapy started. All patients that received at least one dose of immunotherapy were taken into analysis.

      Result

      A total of 158 patients with lung cancer were diagnosed in that period, only 18 patients were assessed, the mean age was 62, and the vast majority had adenocarcinoma. The mean number of cycles was 27 (2-52). The ORR was of 28% , 80% had partial response (PR) and 20% had complete response (CR). Thirty-nine percen had stable disease (SD) while 33% had progressive disease (PD). The median of time to achieve a response was of 11.5 weeks. The response according to the PD-L1 expression was stratified, founding clinical benefit in all the groups. The time to progression since immunotherapy was 15weeks. One case was reported as unconfirmed progressive disease by week 10.

      Markers of inflammation analyzed showed Neutrophil-lymphocyte rate (NLR) and Platelet-lymphocyte rate (PLR) means were 4.37 (1.42 – 21.6) and 270.19 (93.1-650.7)respectively. The values obtained according to response found that the group that progressed to therapy had 4.23 NLR and 343.9 PLR. The group who had clinical benefit, had 4.39 NLR and 229.9 PLR. 33% of the population present toxicity, from which 83% was graded G1-2 and 17% G3-4.

      Conclusion

      A high PLR might be associated with an unfavorable prognosis although more studies are needed. This is the first study in Peruvian population that shows results of immunotherapy in lung cancer.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.